On Friday, Shares of Service Corporation International (NYSE:SCI), lost -2.34% to $28.83.
Service Corporation International, an innovative leader in the funeral and cemetery industry, supports nearly 2,000 widows and widowers across the nation through the Living Information for Recently (LIFT) program, which is designed to reinforce a sense of wholeness and purpose for those who have lost a spouse.
As the nation’s baby boomers continue its steady stream into retirement age, some 800,000 Americans are becoming widows or widowers each year. Many experience different levels of grief, depression or a sense of feeling lost after the death of their spouse. With 50 chapters around the country, SCI LIFT provides widows and widowers who share similar loss experiences with the opportunity to socialize together in a positive and supportive atmosphere without any membership requirements, cost, or obligation.
Service Corporation International, together with its auxiliaries, provides deathcare products and services in the United States and Canada. The company operates through Funeral and Cemetery segments. Its funeral service and cemetery operations comprise funeral service locations, cemeteries, funeral service/cemetery combination locations, crematoria, and related businesses.
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD), inclined 4.30% to $15.53, during its last trading session.
Amicus Therapeutics, a biotechnology company at the forefront of therapies for rare and orphan diseases, and Scioderm, Inc. a privately-held biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, have signed a definitive agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc.
Transaction highlights
- Excellent planned fit with Amicus’ patient-centric vision to develop and commercialize advanced therapies for devastating rare and orphan diseases
- Leverages Scioderm development team’s EB expertise with Amicus’ global clinical infrastructure to advance Zorblisa toward regulatory approvals and Amicus’ commercial, patient advocacy and medical affairs infrastructure to support a successful global launch
- Potential first-to-market therapy to address estimated $1 billion+ global commercial opportunity
- FDA breakthrough therapy designation based on positive Phase 2 proof-of-concept data
- Phase 3 pivotal study (SD-005) is presently enrolling pediatric and adult EB patients across all major subtypes to support global regulatory approvals — data anticipated in 1H16
- Well-defined global regulatory pathway — agreement on rolling NDA in U.S. and pediatric investigation plan (PIP) in Europe
- Creates a leading rare disease portfolio that is well-positioned to bring substantial value to patients and shareholders - potential for Fabry commercial product launch, EB marketing submissions, and Pompe Phase 3 study in 2016
Amicus Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
At the end of Friday’s trade, Shares of Marriott International Inc (NASDAQ:MAR), lost -1.48% to $70.02.
Arne Sorenson, president and chief executive officer at Marriott International, will give the keynote address at the 2015 Bank of America Merrill Lynch Gaming and Lodging Conference, to be held on Wednesday, September 9.
Marriott International, Inc. operates franchises, and licenses hotels and timeshare properties worldwide. It operates through three segments: North American Full-Service, North American Limited-Service, and International.
Finally, Apple Hospitality REIT Inc (NYSE:APLE), ended its last trade with 0.22% gain, and closed at $17.95.
Apple Hospitality REIT declared that it has closed on the formerly declared acquisition of a 245-room Courtyard by Marriott in San Diego, CA for a purchase price of $56 million, or about $229,000 per key.
“We are happy to add the recently renovated Courtyard San Diego Central to our portfolio of upscale hotels and improvement our presence in the dynamic San Diego market,” said Nelson Knight, Executive Vice President, and Chief Investment Officer for Apple Hospitality REIT. “San Diego’s economy is diversified across numerous leisure and corporate demand generators and we believe this hotel is well positioned for future growth.”
In addition to popular leisure activities, the San Diego market provides a wealth of diverse demand generators with an economy marked by a strong military concentration, technology industries and innovative life science research and healthcare organizations. The Courtyard® San Diego Central, located at 8651 Spectrum Center Boulevard in San Diego, is convenient to Qualcomm Stadium, San Diego State University, the University of California San Diego, the San Diego Zoo, Marine Corps Air Station Miramar, SeaWorld San Diego, the Gaslamp Quarter, downtown San Diego and San Diego’s beaches. Hotel industry fundamentals have continued to accelerate across the San Diego market and according to data offered by Smith Travel Research (STR), RevPAR improved by 10.7 percent for the first six months of 2015 as contrast to the same period of 2014.
Apple Hospitality REIT, Inc. is a publicly owned real estate investment trust. It invests in the real estate markets of United States. The firm invests primarily in the lodging industry. It is focused on the acquisition and ownership of income-producing real estate.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
